A Phase 4 interventional study of Prograf and Methotrexate in Graft Versus Host Disease, sponsored by Astellas Pharma Korea, Inc.. Completed at 3 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-01.
Sponsored by Astellas Pharma Korea, Inc. (part of Astellas Pharma Inc) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing tacrolimus in Graft vs Host Disease — 3 open to participants now, 4 under way, none of them phase 3. Tacrolimus · Graft vs Host Disease.
Among the 36 studies testing tacrolimus in Graft vs Host Disease, this one is the 15th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2008, is one of 3 in phase 4, and was the 31st registered.
804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.
Browse Graft vs Host Disease studies →3 of the 36 studies testing tacrolimus in Graft vs Host Disease are open now, in 1 country. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18–75
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages up to 26
City of Hope Medical Center · Sites in United States
Ages 18–80
By country, each count listing its studies:
Tacrolimus: first FDA approval 1994 (PROGRAF), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 28 · Phase 3 4 · Phase 4 3
First in 2000; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is above the median of 35 across 639 interventional studies indexed under Graft vs Host Disease.
Median enrollment 34 across the 32 interventional studies. Of the 32 that completed or were terminated, 15 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Astellas Pharma Korea, Inc., one of the names counted as Astellas Pharma Inc. Under that name alone:
Astellas Pharma Korea, Inc. is the lead sponsor of 19 studies on the registry; 3 are open to participants now.
Astellas Pharma Inc has 3 studies filed under Graft vs Host Disease — fewer than ten, so there is no comparison to draw.
1 of the studies testing tacrolimus in Graft vs Host Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05621759NYU Langone HealthCyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD | 2027-01-30 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing tacrolimus in Graft vs Host Disease, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to assess the safety and efficacy of Tacrolimus (Prograf capsule, Prograf injection) and Methotrexate combination therapy for GVHD prophylaxis in patients who received peripheral hematopoietic stem cell transplantation from a sibling donor, and to compare with data from a historical control group that administered a conventional Cyclosporine formulation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Blood diseases for a standard risk group
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Prograf · Drug: Methotrexate
Drug: Methotrexate · Drug: Cyclosporine
Injection or oral
Also known as: Tacrolimus
Injection
Injection or oral
Number of occurrence sites of acute GVHD occurring within 100 days after peripheral hematopoietic stem cell transplantation from a sibling donor
Time frame: Day 1 up to Day 100 post-transplant
Severity of acute GVHD occurring within 100 days after peripheral hematopoietic stem cell transplantation from a sibling donor
Severity is graded according to the Seattle criteria, between 1+ \~ 4+ depending on the severity of the injury of the skin, liver and digestive system, and the overall grade is classified by including the performance change.
Time frame: Day 1 up to Day 100 post-transplant
Number of occurrence sites of chronic GVHD occurring after 100 days after peripheral hematopoietic stem cell transplantation from a sibling donor
Time frame: Day 100 up to 1 year post-transplant
Classification of chronic GVHD occurring after 100 days after peripheral hematopoietic stem cell transplantation from a sibling donor
Depending on the extent of occurrence, it is classified as limited (present only locally) and extensive (systemic lesions). Depending on the presence of preceding acute GVHD, it is classified as progressive for a patient with preceding acute GVHD (chronic GVHD following the occurrence of acute GVHD), quiescent (chronic GVHD after relief of acute GVHD symptoms) or otherwise (de novo).
Time frame: Day 100 up to 1 year post-transplant
Safety as assessed by adverse events
Time frame: Day 1 up to 1 year post-transplant
Safety as assessed by laboratory assessments
Includes hematology, biochemistry and trough plasma concentration analysis
Time frame: Day 1 up to 1 year post-transplant
Percentage of patients alive after peripheral hematopoietic stem cell transplantation from a sibling donor
Time frame: Day 1 up to 1 year post-transplant
Percentage of patients alive after peripheral hematopoietic stem cell transplantation from a sibling donor in comparison with Cyclosporine in combination with MTX
Time frame: Day 1 up to 1 year post-transplant
Plan to share: Undecided
The record gives a start of Feb 2008, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tacrolimus